Regenerative Medicine Market in Japan 2016-2020


#834764

102pages

Technavio

$ 2500

In Stock

About Regenerative Medicine

Regenerative medicine deals with the process of using therapeutically induced or laboratory-grown human tissue to treat damaged or diseased human cells, tissues, or organs. It focuses on repairing, replacing, or regenerating damaged cells, and thus offers a paradigm shift in healthcare treatment. The three main technologies used in regenerative medicine are small molecules and biologics, gene therapy, and cell therapy. Small molecules and biologics help in the regeneration of diseased cells and tissues, whereas cell therapy helps in treating the functioning of existing cells.

Technavios analysts forecast the regenerative medicine market in Japan to grow at a CAGR of 35.3% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the regenerative medicine market in Japan for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of various types of regenerative medicine products to end-users like hospitals, ambulatory surgical centers (ASCs), and clinical research laboratories.

The market is divided into the following segments based on product:
Tissue Scaffold
Cell Therapy

Technavio's report, Regenerative Medicine Market in Japan 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
CellSeed
JCR Pharmaceuticals
Japan Tissue Engineering
Terumo
Astellas
Caladrius Biosciences
Healios
Fujifilm
Rohto Pharmaceuticals

Other prominent vendors
FUJISOFT Tissue Engineering
MediBIC
MEDI NET
Nikon
TAKARA
CMIC
EPS
Cyfuse Biomedical
Irvine Scientific
Kaken
Regience
Sumitomo Dainippon
Takeda
Alfresa
MEDIPAL Holdings
TOHO

Market driver
Growing partnerships of MNCs with local vendors in Japan
For a full, detailed list, view our report

Market challenge
High cost and failure rate in clinical trials coupled with inadequate clinical evidence
For a full, detailed list, view our report

Market trend
Strong pipeline portfolio of regenerative medicines
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Healthcare reforms in Japan
PART 06: Regulatory landscape in Japan
ASRM
PMD Act
PART 07: Reimbursement scenario
Reimbursement scenario for regenerative medicine in Japan
PART 08: Gene therapy: An emerging field in regenerative medicine
PART 09: Pipeline portfolio
PART 10: Market landscape
Market overview
Five forces analysis
PART 11: Market segmentation by product
Cell therapy
Cell therapy regenerative medicine market in Japan
Tissue scaffold
Tissue scaffold regenerative medicine market in Japan
PART 12: Market segmentation by application
Dermatology
Musculoskeletal
Cardiovascular
Other
PART 13: Market drivers
Transformation of regulatory landscape fostering quick approval of regenerative medicines
Growing partnerships of MNCs with local vendors in Japan
Recent product approvals fuel the market growth
Government initiatives driving regenerative medicine market in Japan
PART 14: Impact of drivers
PART 15: Market challenges
Ethical challenges involved in regenerative medicine
High cost and failure rate in clinical trials coupled with inadequate clinical evidence
Low competitive edge of Japanese regenerative medicine market over other developed nations
PART 16: Impact of drivers and challenges
PART 17: Market trends
Strong pipeline portfolio of regenerative medicines
Entry of new players expanding the applications of regenerative medicine
Strategic collaborations and acquisitions
Advent of 3D tissue bioprinters for the development of regenerative medicines
PART 18: Vendor landscape
Competitive scenario
Key news
Product approvals
Partnerships
Mergers and acquisitions
Other
PART 19: Key vendor analysis
CellSeed
JCR Pharmaceuticals
Japan Tissue Engineering (J-TEC)
Terumo
Upcoming vendors
Other prominent vendors
PART 20: Appendix
List of abbreviations
PART 21: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Regenerative medicine application in various therapeutics
Exhibit 03: Major applications of regenerative medicine in Japan
Exhibit 04: Regenerative medicine legislation acts in Japan
Exhibit 05: Product approval and regulatory characteristics in Japan
Exhibit 06: Overview of regenerative medicine regulation acts
Exhibit 07: Landscape of regenerative medicine in Japan
Exhibit 08: Risk categories of regenerative medical technologies
Exhibit 09: Regenerative medicine approval process in Japan under the ASRM
Exhibit 10: Regenerative medicine approval process in Japan under PMD Act
Exhibit 11: Comparison of traditional and new product approval process under the PMD Act
Exhibit 12: Conditional approvals for regenerative medical products versus regular approval for pharmaceuticals
Exhibit 13: Japans NHI pricing methods
Exhibit 14: NHI pricing calculation for TEMCELL HS
Exhibit 15: NHI pricing calculation for HeartSheet A kit
Exhibit 16: NHI pricing calculation for HeartSheet B kit
Exhibit 17: Gene therapy research by sponsorship
Exhibit 18: Regenerative medicine pipeline products in Japan
Exhibit 19: Pipeline analysis of regenerative medicine in Japan 2015
Exhibit 20: Pipeline products of regenerative medicine for cell therapy in 2015
Exhibit 21: Key developments in regenerative medicine market in Japan 2015
Exhibit 22: Regenerative medicine market in Japan 2015-2020 ($ millions)
Exhibit 23: Regenerative medicine market in Japan: Optimistic and pessimistic analyses 2015-2020
Exhibit 24: Optimistic and pessimistic market analysis of regenerative medicine in Japan 2015-2020
Exhibit 25: Five forces analysis
Exhibit 26: Regenerative medicine market in Japan by product 2015 and 2020
Exhibit 27: Positioning of segments (by product type) in regenerative medicine market in Japan 2015
Exhibit 28: Regenerative medicine market in Japan: Lifecycle analysis by product 2015
Exhibit 29: Cell therapy overview
Exhibit 30: Ethical issues involved in different cell therapy research category
Exhibit 31: Stem cell research policies in Japan
Exhibit 32: Key cell therapy products marketed in Japan
Exhibit 33: Cell therapy regenerative medicine market in Japan 2015-2020 ($ millions)
Exhibit 34: Opportunity analysis of cell therapy regenerative medicine market in Japan
Exhibit 35: Collaborations for R&D of tissue scaffold
Exhibit 36: Tissue scaffold regenerative medicine market in Japan 2015-2020 ($ millions)
Exhibit 37: Opportunity analysis of tissue scaffold in Japan regenerative medicine market
Exhibit 38: Regenerative medicine market in Japan by product type 2015-2020 ($ millions)
Exhibit 39: Regenerative medicine market in Japan 2015-2020 (%)
Exhibit 40: Overview of the regenerative medicine dermatology market in Japan
Exhibit 41: Pipeline of regenerative medicine for dermatology
Exhibit 42: Overview of musculoskeletal regenerative medicine market in Japan
Exhibit 43: Overview of cardiovascular regenerative medicine market in Japan
Exhibit 44: Regulatory guidelines in Japan
Exhibit 45: Approval process of SAKIGAKE assignment system
Exhibit 46: Partnerships of MNCs with local vendors in Japan
Exhibit 47: MHLW budget on drug discovery using iPS cells ($ millions)
Exhibit 48: Impact of drivers
Exhibit 49: Force field analysis of regenerative medicine market in Japan
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Regenerative medicine pipeline portfolio 2015
Exhibit 52: Current applications of regenerative medicine
Exhibit 53: Future applications of regenerative medicine
Exhibit 54: Major strategic collaborations and acquisitions in Japan
Exhibit 55: Impact of trends in regenerative medicine in Japan 2015-2020
Exhibit 56: Presence of vendors in regenerative medicine
Exhibit 57: CellSeed: Profile
Exhibit 58: CellSeed: Strength analysis
Exhibit 59: CellSeed: Growth strategy matrix
Exhibit 60: CellSeed: Opportunity assessment
Exhibit 61: JCR Pharmaceuticals: Profile
Exhibit 62: JCR Pharmaceuticals: Strength analysis
Exhibit 63: JCR Pharmaceuticals: Growth strategy matrix
Exhibit 64: JCR Pharmaceuticals: Opportunity assessment
Exhibit 65: J-TEC: Profile
Exhibit 66: J-TEC: Strength analysis
Exhibit 67: J-TEC: Growth strategy matrix
Exhibit 68: J-TEC: Opportunity assessment
Exhibit 69: Terumo: Profile
Exhibit 70: Terumo: Strength analysis
Exhibit 71: Terumo: Growth strategy matrix
Exhibit 72: Terumo: Opportunity assessment